ArticleBreast cancer (Tokyo, Japan)2026
UGT2B17 as a predictive biomarker of complete pathological response in HER2 + breast cancer.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPathological complete response (pCR) after neoadjuvant therapy is a robust surrogate marker for long-term outcomes in breast cancer. Despite major advances with targeted therapies, a significant proportion of patients fail to achieve pCR, underscoring the urgent need for reliable biomarkers that can predict treatment response and guide patient stratification.
methodsWe conducted a two-phase study including 53 patients with HER2-positive, hormone receptor–negative breast cancer treated with neoadjuvant chemotherapy plus anti-HER2 agents. Transcriptomic profiling (discovery cohort, n = 13) identified differentially expressed genes associated with therapeutic response, which were validated by qPCR in an independent cohort (n = 40). Functional enrichment analysis was performed to explore the biological pathways underlying the differential response.
resultsDifferential expression analysis revealed 6251 genes associated with response, with significant enrichment in xenobiotic metabolism and steroid hormone biosynthesis pathways. Within these, members of the UGT2B family (UGT2B10, UGT2B17, UGT2B28) were overexpressed in non-responders. Validation confirmed UGT2B17 (p = 0.023, AUC = 0.699, sensitivity 77.2%, specificity 64.5%) and UGT2B28 (p = 0.046, AUC = 0.677) as predictive biomarkers of resistance to neoadjuvant therapy. UGT2B17 showing the highest discriminative value.
conclusionsUGT2B17 overexpression is associated with resistance to neoadjuvant therapy in HER2-positive breast cancer, supporting its potential role as a predictive biomarker. Integration of UGT2B17 into molecular panels could improve patient stratification and guide personalized therapeutic strategies in this subtype.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.